Interactions of Ionophoric Polyphenols with Human Serum Albumin

The distribution of a drug is determined, at least in part, by its interactions with serum proteins. Human serum albumin (HSA), the most abundant blood plasma protein, serves as the most common mode of transport for drugs to their target. In our previous work, we have synthesized and studied important characteristics of a series of ionophoric polyphenols as potential anti‐Alzheimer’s disease agents. As part of our ongoing investigations on the biological activity of these compounds, we are now exploring possible transport mechanisms. In our current work, the interactions of the ionophoric polyphenols with HSA were studied via in vitro and in silico methods. In line with in vitro studies, the interaction of the ionophoric polyphenols with HSA were studied by fluorescence and circular dichroism (CD) spectroscopies to obtain binding affinities, bimolecular quenching constants, theoretical number of binding sites and HSA secondary structural changes. Moreover, in line with in silico studies, a preferred mode of binding was predicted by molecular docking and the predicted systems were subject to a 5 ns MD simulation; consequently, RMSD studies were performed to attest for stability of the systems, MM/GBSA binding free energies were calculated to correlate with experimental binding affinities and per‐residue energy decomposition analyses were carried out to analyze residues critical to binding. Using resveratrol, a polyphenolic compound which has demonstrated strong neuroprotective and anti‐Alzheimer disease properties, as a control, in vitro results showed the formation of adducts (static quenching), one theoretical binding site, binding constants (Ka) ranging 10 4 to 10 6 M −1 and only slight secondary structure modifications between HSA and the ionophoric polyphenols. Further, in silico results revealed the ionophoric polyphenols and resveratrol favorably binding subdomain IIA of HSA, forming critical interactions to Trp 214 and Asp451. RMSD studies showed the HSA‐IIA system plateauing after a short time indicating stable binding events; in addition, a Pearson correlation coefficient of R=0.80 between the experimental binding affinity and computational binding free energies showed a strong correlation between in vitro and in silico results. Overall, our results seem to indicate that there is a ionophoric polyphenol‐serum albumin interaction, which could have a potential impact on the use of ionophoric polyphenols as therapeutics for Alzheimer’s disease. Support or Funding Information This research used resources of the National Energy Research Scientific Computing Center (NERSC), a U.S. Department of Energy Office of Science User Facility operated under Contract No. DE‐AC02‐05CH11231.